Re: To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia

References

1. 1.↵
   1. Tien YY,
   2. Shih MC,
   3. Tien CP,
   4. Huang HK,
   5. Tu YK

   . To treat or not to treat? Effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta-analysis. J Am Board Fam Med 2022;35:140–51.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Gao L,
   2. Wang B,
   3. Pan Y,
   4. Lu Y,
   5. Cheng R

   . Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clin Cardiol 2021;44:907–16.

   OpenUrl
3. 3.↵
   1. White WB,
   2. Saag KG,
   3. Becker MA,
   4. et al

   ; CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med 2018;378:1200–10.

   OpenUrlPubMed
4. 4.↵
   1. Mackenzie IS,
   2. Ford I,
   3. Nuki G,
   4. et al

   . Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 2020;396:1745–57.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Choi HK,
   2. Neogi T,
   3. Stamp LK,
   4. Terkeltaub R,
   5. Dalbeth N

   . Reassessing the cardiovascular safety of febuxostat: implications of the febuxostat versus allopurinol streamlined trial. Arthritis Rheumatol 2021;73:721–4.

   OpenUrl